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co-occurrence of symptoms of Attention Deﬁ cit Hyperactivity Disorder (ADHD), a
neurobehavioral condition that impairs organization and executive planning that
affects between 1–6% of adults in the United States. METHODS: The study design 
utilized an internet-based panel of 567 T2DM cases that consented to participate in 
a survey. In addition to de-identiﬁ ed demographic data, respondents were asked to
provide information on diabetes self-care, HbA1c values, ADHD symptoms, and 
health care resource utilization. RESULTS: The results indicated that those respon-
dents who had symptoms of ADHD had more ofﬁ ce visits for diabetes-related issues 
(p  .0002), more ofﬁ ce visits for illness or injury (p  .0007), and more hospitaliza-
tions for illness or injury (p  .0493) compared with T2DM respondents without
symptoms of ADHD. For those who reported HbA1c values, regression tree analyses
suggested low diabetes self-care scores and high ADHD symptom scores were associ-
ated with worse HbA1c values. CONCLUSIONS: These ﬁ ndings suggest that the co-
occurrence of T2DM and ADHD symptoms could result in poor HbA1c management
and may lead to increased resource utilization.
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OBJECTIVES: Functioning in severe mental disorders is very important and brief 
rating instruments are needed. Personal and Social Performance Scale (PSP) is one of 
the instruments which can be used in severe mental disorders in a short time.
METHODS: The study was performed in the psychiatry departments of two university 
hospitals. In- or outpatients diagnosed as schizophrenia or bipolar disorder were
included in the study. Exclusion criteria were comorbidity of other psychiatric disorders
(including substance use disorders) and physical diseases. For concurrent validity,
besides PSP, Clinical Global Impression (CGI), Global Assessment of Functioning
(GAF) of DSM-IV, Quality of Life and Satisfaction Questionnaire (QLS-Q), and Posi-
tive and Negative Schizophrenia Scale (PANSS) were used. For discriminant validity,
the mean scores of PSP of patients with and without symptomatic remission were
compared. RESULTS: The study was carried out with a total of 135 patients, 105
(77.8%) diagnosed as schizophrenia and 30 (22.2%) diagnosed as bipolar disorder. 
The mean age of the patients was 34.1 o 10.7 and 75 (55.6%) of them were male. The
duration of illness was 10.4 o 7.5 years. The mean score of PSP was 60.0 o 17.1. In
the reliability analysis, the Cronbach alpha coefﬁ cient was 0.8327, and item-total score
correlations were between 0.4920–0.7462. In the validity analyses, the total score of 
PSP was signiﬁ cantly correlated with the total score of CGI (r  0.854, p  0.0001), 
GAF (r  0.748, p  0.0001), QLS-Q (r  0.734, p  0.0001), and PANSS (r  0.664, 
p  0.0001). The difference between the patients with and without symptomatic remis-
sion was signiﬁ cant (54.8 o 14.8 vs. 72.6 o 9.8, t  7.434, p  0.0001). CONCLU-
SIONS: The Turkish version of PSP was found to be reliable and valid in severe mental
disorders. It can be used both in clinical trials and routine follow-up.
PMH51
PSYCHOMETRIC PROPERTIES OF THE LIFE PARTICIPATION SCALE FOR
ADULTS ASSESSING DEFICITS IN ADAPTIVE FUNCTIONING
Saylor KE1, Sutton V2, Khan SA3
1Neuroscience, Inc, Herndon, VA, USA, 2i3 Research, Cary, NC, USA, 3Eli Lilly and Company, 
Indianapolis, IN, USA
OBJECTIVES: The Life Participation Scale for Children was designed to measure
treatment-related improvements in adaptive functioning in children with ADHD. To
measure these attributes in adult subjects, we developed a Life Participation Scale for 
Adults (LPS-A). METHODS: LPS-A items were selected by convening focus groups, 
interviewing experts, and performing structured cognitive interviews to improve item
wording. These were administered in a 2-week study of treated (N  10) and untreated 
(N  10) participants with ADHD and normal controls (N  11). Cronbach’s alpha,
Lin’s concordance correlation, and Pearson’s correlations were used to assess internal
consistency, test-retest reliability, and convergent/divergent validity. LPS-A scores were
compared for ADHD/control, treated/untreated, and less/more severe participants to 
measure discriminant validity. RESULTS: The LPS-A demonstrated internal consis-
tency (Cronbach’s alpha  0.92–0.96). Concordance correlations indicated test-retest 
reliability (r  0.79 to 0.86). Convergent, divergent, and discriminant validity were 
demonstrated. CONCLUSIONS: The initial examination of the LPS-A suggests accept-
able levels of validity and reliability. Larger studies will provide further information 
about the psychometric properties of the LPS-A. The LPS-A appears to be a promising 
new instrument for measuring adaptive function in adults with ADHD.
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OBJECTIVES: Previous studies (prior to 2003) have suggested that central nervous 
system (CNS) drugs have had the highest number of patient-reported outcomes (PRO)
claims used in product approvals. This study examined the use of PRO as efﬁ cacy 
endpoints in label claims of recent FDA-approved CNS drugs between 2003 and 2008. 
METHODS: Product labels of FDA-approved prescription-only New Molecular Enti-
ties (NMEs) from the CNS drug category between January 2003 and October 2008 
were reviewed. The most recent product label, obtained either from the FDA’s Center
for Drug Evaluation and Research (CDER) or directly from the company website, was 
used for all the drugs, including the drugs withdrawn from the market. Efﬁ cacy end-
point data was obtained from the Clinical Studies section of the approved product 
label. Efﬁ cacy measures were categorized into PRO, clinician-reported outcomes
(CRO) and laboratory devices. RESULTS: During the ﬁ ve year period, 14 of the 153
FDA-approved NMEs were CNS agents. The CNS agents included four drugs for 
neuromuscular disorders, two antipsychotics, two antidepressants, two sedatives, one
smoking cessation drug, one analgesic, one CNS stimulant, and one drug treating 
alcoholism. Of the 28 efﬁ cacy measures used in the CNS product labels, seven (25%) 
were PRO. The four drugs using PRO endpoints included one antidepressant, one
analgesic, one CNS stimulant and one smoking cessation drug. Of the seven PRO 
used, three were symptom scales, two were global impression scales, one scale mea-
sured condition-speciﬁ c health-related quality-of-life, and one scale measured func-
tional impairment. The percentage of approved CNS drugs using PRO as efﬁ cacy
endpoints in label claims declined since 2002 (2003–08: 28.5%; 1997–2002: 75%). 
CONCLUSIONS: The latter half of the past decade has seen a considerable decrease 
in the number of CNS drugs that have had PRO-based label claims. Symptoms scales 
are the prominent type of PRO used in CNS drug label claims.
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OBJECTIVES: To identify the clinical outcomes associated with self-perceived copay 
burden among patients with schizophrenia. METHODS: Data were taken from a 
nationwide survey of adults (age 18) with a self-reported diagnosis of schizophrenia.
The survey was ﬁ elded from December 2007 to February 2008. Data were collected 
through both self-reported questionnaires administered on-site, and via the Internet.
Inclusion criteria for analysis were no exposure to clozapine, no use of a depot injec-
tion of an antipsychotic, and currently using a second generation antipsychotic (SGA). 
Outcomes included emergency room (ER) visits, hospitalization, suicide attempt, 
missed work (among employed patients), as well as experiencing severe distress deﬁ ned 
as a score of 0–60 on the Psychological General Well Being (PGWB) scale. Assessment
of the effects of self-perceived copay burden on outcomes was calculated using logistic
regression models. Demographics, substance use, concomitant psychotropic medica-
tions, comorbidity, and health insurance were controlled for in the models. RESULTS:
Of the patients who met the inclusion criteria (n  351), 39% (n  137) self-reported 
experiencing copay burden. Adjusting for covariates, patients who experienced copay
burden were more likely to use the ER [OR  2.157; 95% CI:(1.322, 3.520); p 
0.002], have a hospitalization [OR  2.512; 95% CI: (1.475, 4.277); p  0.001], have 
a suicide attempt [OR  2.385; 95% CI: (1.156, 4.920); p  0.019], and experience
severe psychological distress [OR  1.833; 95% CI: (1.092, 3.075); p  0.022]. Among 
the 110 patients who were employed, those who experienced copay burden were more 
likely to have missed work in the past month [OR  7.193; 95% CI: (2.554, 20.256);
p  0.001]. CONCLUSIONS: Among patients with schizophrenia using SGAs, greater 
copay burden was associated with increased ER visits, hospitalization, suicide 
attempts, missed work, and psychological distress. Patient’s health care use and psy-
chological well being are likely to beneﬁ t from less restrictive formularies that reduce 
copay burden for antipsychotic medication.
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OBJECTIVES: Our objective was to examine the association of health status measures
with depression diagnosis in chronic medical disorder (CMD) patients. METHODS:
For the retrospective analysis, we extracted data on / 18 year-old employed adults 
from the pooled 2004–5 Medical Expenditure Panel Survey. Data included ICD-9-
CM-coded CMD (hyperlipidemia, heart-disease, arthritis/other joint-disorders, 
chronic obstructive pulmonary disease, hypertension, or diabetes), depression, age,
gender, race, poverty-level, health-insurance, urban-residence, and any depression 
treatment (psychotherapy or antidepressant) and patient-reported health-status mea-
sures (physical component summary, PCS, and mental component summary, MCS 
scores from the Short-Form 12 (SF-12); patient health questionnaire, PHQ-2; and 
Kessler Index, K6) on a continuous scale. We compared mean and standard deviation 
of health status measures in CMD patients with and without depression using t-tests. 
We weighted sample estimates and calculated 95 percent conﬁ dence limits (CL) using 
the Taylor expansion method. In multivariate logistic regression analyses, after con-
trolling for other characteristics, we examined the association of health status mea-
sures with depression diagnosis. RESULTS: Health status signiﬁ cantly differed in
CMD patients with and without depression (n  9,738, Means; SF-12 PCS 48.25 vs.
50, SF-12 MCS 43.76 vs. 52.03, PHQ-2 1.59 vs. 0.53, and K6 6.3 vs. 2.9, all 
p  0.001). Increasing scores on the SF-12 PCS and SF-12 MCS decreased the odds 
of depression while increasing scores on the PHQ-2 and K6 increased the odds of 
depression. In a multivariate model, after adjusting for covariates, the SF-12 MCS (a 
one-unit increase resulted in 0.97 times the risk for depression, 95%CL: 0.95–0.99, 
p  0.0009) and the PHQ-2 (a one-unit increase results in 1.2 times the risk for 
depression, 95%CL: 1.07–1.35, p  0.0022) were signiﬁ cantly associated with depres-
